Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Healthtrust
McKesson
Queensland Health
US Army
Mallinckrodt

Generated: September 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,539,258

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,539,258 protect, and when does it expire?

Patent 9,539,258 protects GILOTRIF and is included in one NDA.

This patent has ten patent family members in four countries.

Summary for Patent: 9,539,258
Title:Quinazoline derivatives for the treatment of cancer diseases
Abstract: The present invention relates to the use of quinazolines of formula (I), ##STR00001## wherein the groups R.sup.a to R.sup.d have the meanings given in the claims and specification, in cancer therapy.
Inventor(s): Solca; Flavio (Vienna, AT), Amelsberg; Andree (Southbury, CT), van Meel; Jacobus C. A. (Moedling, AT), Baum; Anke (Moedling, AT), Stehle; Gerd (Ehingen, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:14/739,299
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,539,258
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,539,258

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim GILOTRIF afatinib dimaleate TABLET;ORAL 201292-001 Jul 12, 2013 RX Yes No   Try a Free Trial   Try a Free Trial TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY   Try a Free Trial
Boehringer Ingelheim GILOTRIF afatinib dimaleate TABLET;ORAL 201292-002 Jul 12, 2013 RX Yes No   Try a Free Trial   Try a Free Trial TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY   Try a Free Trial
Boehringer Ingelheim GILOTRIF afatinib dimaleate TABLET;ORAL 201292-003 Jul 12, 2013 RX Yes Yes   Try a Free Trial   Try a Free Trial TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,539,258

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
05110656Nov 11, 2005

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Mallinckrodt
McKesson
Medtronic
AstraZeneca
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.